
USD
+$0.00
(+0.00%
)At Close (As of Nov 28, 2025)
$1.23B
Market Cap
8.3
P/E Ratio
0.66
EPS
$5.72
52 Week High
$2.47
52 Week Low
HEALTHCARE
Sector
| Field | Value (EUR) |
|---|---|
| Gross Profit | $429M |
| Total Revenue | $535M |
| Cost Of Revenue | $106M |
| Costof Goods And Services Sold | $106M |
| Operating Income | $178M |
| Selling General And Administrative | $70M |
| Research And Development | $153M |
| Operating Expenses | $252M |
| Investment Income Net | - |
| Net Interest Income | $12M |
| Interest Income | $12M |
| Interest Expense | $0 |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $19M |
| Income Before Tax | $191M |
| Income Tax Expense | $29M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $162M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $191M |
| Ebitda | $210M |
| Net Income | $162M |
| Field | Value (EUR) |
|---|---|
| Total Assets | $803M |
| Total Current Assets | $526M |
| Cash And Cash Equivalents At Carrying Value | $482M |
| Cash And Short Term Investments | $482M |
| Inventory | $541K |
| Current Net Receivables | $33M |
| Total Non Current Assets | $276M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $13M |
| Intangible Assets Excluding Goodwill | $13M |
| Goodwill | $12M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $3.6M |
| Other Current Assets | $7.6M |
| Other Non Current Assets | - |
| Total Liabilities | $106M |
| Total Current Liabilities | $72M |
| Current Accounts Payable | $17M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $5.3M |
| Total Non Current Liabilities | $34M |
| Capital Lease Obligations | $39M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $39M |
| Other Current Liabilities | $32M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $697M |
| Treasury Stock | - |
| Retained Earnings | -$1.4B |
| Common Stock | $27M |
| Common Stock Shares Outstanding | $225M |
| Field | Value (EUR) |
|---|---|
| Operating Cashflow | $102M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $19M |
| Capital Expenditures | $18M |
| Change In Receivables | - |
| Change In Inventory | $590K |
| Profit Loss | - |
| Cashflow From Investment | -$18M |
| Cashflow From Financing | -$5.1M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $191M |
| Field | Value (EUR) |
|---|---|
| Gross Profit | $429M |
| Total Revenue | $535M |
| Cost Of Revenue | $106M |
| Costof Goods And Services Sold | $106M |
| Operating Income | $178M |
| Selling General And Administrative | $70M |
| Research And Development | $153M |
| Operating Expenses | $252M |
| Investment Income Net | - |
| Net Interest Income | $12M |
| Interest Income | $12M |
| Interest Expense | $0 |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $19M |
| Income Before Tax | $191M |
| Income Tax Expense | $29M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $162M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $191M |
| Ebitda | $210M |
| Net Income | $162M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
CureVac NV (CVAC) is a clinical-stage biopharmaceutical innovator based in Tübingen, Germany, specializing in cutting-edge messenger RNA (mRNA) technology. The company is dedicated to developing a diverse pipeline of mRNA-based vaccines and therapeutics targeting critical unmet medical needs in areas such as infectious diseases and oncology. With a strong scientific foundation and strategic partnerships, CureVac is poised to significantly impact the expanding mRNA sector, aiming to transform healthcare solutions both in Europe and worldwide.